Cardiovascular Health during and after Cancer Therapy

Ruddy, Kathryn J.; Patel, Shruti; Higgins, Alexandra; Armenian, Saro H.; Herrmann, Joerg

doi:10.3390/cancers12123737

Cited by 15 publications

(11 citation statements)

References 108 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The mechanisms of cardiotoxicity are not equally understood in all chemotherapeutics, however. The pathophysiology of HER-2-targeting agents, used for the treatment of breast cancer, is currently unclear ( 56 ). Further studies into the mechanisms of chemotherapy-induced cardiotoxicity for various treatments could serve to improve future therapeutic developments.…”

Section: Discussionmentioning

confidence: 99%

Shared Genetic Risk Factors Between Cancer and Cardiovascular Diseases

Turk

Kunej

2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Cancer and cardiovascular diseases (CVD) account for approximately 27.5 million deaths every year. While they share some common environmental risk factors, their shared genetic risk factors are not yet fully understood. The aim of the present study was to aggregate genetic risk factors associated with the comorbidity of cancer and CVDs. For this purpose, we: (1) created a catalog of genes associated with cancer and CVDs, (2) visualized retrieved data as a gene-disease network, and (3) performed a pathway enrichment analysis. We performed screening of PubMed database for literature reporting genetic risk factors in patients with both cancer and CVD. The gene-disease network was visualized using Cytoscape and the enrichment analysis was conducted using Enrichr software. We manually reviewed the 181 articles fitting the search criteria and included 13 articles in the study. Data visualization revealed a highly interconnected network containing a single subnetwork with 56 nodes and 146 edges. Genes in the network with the highest number of disease interactions were JAK2, TTN, TET2, and ATM. The pathway enrichment analysis revealed that genes included in the study were significantly enriched in DNA damage repair (DDR) pathways, such as homologous recombination. The role of DDR mechanisms in the development of CVDs has been studied in previously published research; however, additional functional studies are required to elucidate their contribution to the pathophysiology to CVDs.

show abstract

Section: Discussionmentioning

confidence: 99%

Shared Genetic Risk Factors Between Cancer and Cardiovascular Diseases

Turk

Kunej

2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…Используются различные комбинации, основанные на струйных или длительных введениях 5-ФУ. У 1,2-18% https://doi.org/10.17816/22217185.2021.3.201098 пациентов, проходящих лечение 5-ФУ, отмечаются проявления кардиотоксичности [7]. По другим данным, показатель кардиотоксичности 5-ФУ составляет от 1,1 до 7,6% [13].…”

Section: кардиотоксичность антиметаболитовunclassified

“…Если терапии 5-ФУ нельзя избежать или заменить, необходимо предварительно за 48 ч провести профилактику БКК или рассмотреть возможность пролонгированного действия нитратов при постоянном ЭКГ-мониторинге [6]. Триацетат уридина одобрен для применения у пациентов с тяжелой и опасной для жизни токсичностью 5-ФУ, в том числе сердечно-сосудистой природы [7].…”

Section: кардиотоксичность антиметаболитовunclassified

“…Кардиотоксичность может развиться как во время химиотерапии, так и в различные сроки после ее окончания. Проявления ее многообразны, могут протекать без симптомов и регистрироваться только при инструментальном исследовании (например, при электрокардиографии -ЭКГ) либо сопровождаться тяжелой, угрожающей жизни клинической картиной [7,8]. Детали этиологии и патогенеза многих отсроченных сердечнососудистых осложнений в настоящее время недостаточно хорошо изучены.…”

Section: Introductionunclassified

See 1 more Smart Citation

Cardiotoxic effects induced by the use of antimetabolites in the chemotherapy of oncological diseases

Aliab'eva

Маль

2021

CardioSomatics

View full text Add to dashboard Cite

In modern medical practice, the treatment of cancer is one of the most pressing issues. Many of the drugs used in the treatment of cancer have a toxic effect on the cardiovascular system of patients. The main clinical manifestations of cardiotoxicity are ischemic heart damage, rhythm disturbances, thrombosis, angina, asymptomatic changes in the electrocardiogram, and others. Side effects can develop both during the treatment period and months after the end of the course of chemotherapy. This is especially important for patients with concomitant cardiac or vascular pathology, since the severity of developing side effects can lead to disability or death of cancer survivors. The article discusses the data on the frequency of detection of the negative effect of pyrimidine, purine and folic acid antagonists on the cardiovascular system of cancer patients, the mechanisms of cardiotoxic effects of drugs in such patients, the possibilities of preventing heart damage and correcting for already developed lesions. The aim of this work is to collect, compare and systematize the available disparate data on the cardiotoxic effects of antitumor drugs of the antimetabolite group. An important condition for saving and preserving the quality of life of cancer patients is the identification of cardiovascular pathologies at the stage of preparation for chemotherapy, which can be facilitated by the active cooperation of oncologists and cardiologists. The search for information was carried out on the bases of scientific medical publications (eLibrary.ru, PubMed) taking into account the clinical recommendations for the treatment of malignant neoplasms.

show abstract

“…Paradoxically, the benefits obtained with the new treatments have been accompanied by an increase in morbidity, with cardiovascular disease (CVD) being the second cause of morbidity and the main cause of death in cancer survivors [ 7 - 8 ]. This complication can occur acutely or chronically, and even several years after completion of therapy [ 7 , 9 ].…”

Section: Introductionmentioning

confidence: 99%

Cardio-oncology Clinical Assessment and Screening in Patients Undergoing High Toxicity Chemotherapy: A Retrospective Cohort Study

Regino¹,

Cardona-Vélez²,

Simanca³

et al. 2022

Cureus

View full text Add to dashboard Cite

Objective: To describe the clinical characteristics and cardio-oncological assessment in patients undertaking highly toxic chemotherapy and/or chest radiotherapy in a high-complexity hospital.Methods: A single-center retrospective cohort study was carried out between January 1st, 2017 and December 31st, 2019. The medical records of patients with solid or hematological neoplasms were reviewed. Descriptive information was obtained on demographic characteristics, chemotherapeutic agents, prechemotherapy cardiovascular (CV) evaluation, and CV outcomes. The risk of complications was assessed using the Mayo Clinic risk score.Results: A total of 499 patients were included, the most common neoplasm was non-Hodgkin's lymphoma (21.6%), followed by breast cancer (19.4%). A very high risk of cardiotoxicity was present in 44.1% and 90% were not evaluated by cardiology. Pre-chemotherapy echocardiography was obtained in 65%, but only 19.4% underwent echocardiographic control after finishing chemotherapy. The most frequent CV outcomes were chemotherapy-related systolic dysfunction (4.4%) and rhythm disturbances (2.8%), with atrial fibrillation and atrial flutter being the most frequent arrhythmias.Conclusion: Despite the recognized CV toxicity of chemotherapeutic drugs, the majority of patients receiving highly toxic regimens at high risk of CV complications are not previously evaluated by a cardiologist and the CV workup was not routinely used in our study. The implementation of cardio-oncology programs will facilitate the identification of high-risk patients, aiming to detect and treat complications early.

show abstract

Cardiovascular Health during and after Cancer Therapy

Cited by 15 publications

References 108 publications

Shared Genetic Risk Factors Between Cancer and Cardiovascular Diseases

Shared Genetic Risk Factors Between Cancer and Cardiovascular Diseases

Cardiotoxic effects induced by the use of antimetabolites in the chemotherapy of oncological diseases

Cardio-oncology Clinical Assessment and Screening in Patients Undergoing High Toxicity Chemotherapy: A Retrospective Cohort Study

Contact Info

Product

Resources

About